Neoplasm Metastasis

The supplied grounding does not support a specific causal aetiology for metastasis beyond its occurrence as spread from a primary neoplasm. The reviews indicate that metastatic progression is driven by genetic and epigenetic changes in tumor cells and by interactions with the tumor microenvironment. No single external cause is established in the grounding.

Metastasis involves invading tumor cells acquiring mobility and plasticity, interacting with proteins, cells, and the tumor microenvironment during dissemination. The process is linked to epithelial-mesenchymal transition, altered signal transduction, gene expression regulation, cell movement, and cell proliferation, as well as immune evasion and stromal adaptation at distant sites. Cancer-associated fibroblasts, tumor-associated macrophages, and immune context within the tumor microenvironment are described as important contributors to invasion, colonization, and therapy resistance.

The grounding does not provide specific patient-level risk factors for developing metastasis. It does indicate that a permissive tumor microenvironment, immune suppression, cancer-associated fibroblasts, and tumor-associated macrophages are associated with metastatic progression. Drug resistance is also described as a feature that can accompany advanced disease.

The supplied grounding supports treatment at the modality and drug-class level rather than a single standard regimen. It includes surgery and chemotherapy, targeted therapy such as anti-EGFR and anti-angiogenesis approaches, immune checkpoint inhibitors, and other targeted agents used in metastatic disease. The literature also highlights biomarker-guided and microenvironment-informed approaches, including therapies directed at immune checkpoints and other critical signaling pathways.